LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Novan, Inc. (“Novan” or the “Company”) (NASDAQ: NOVN) investors concerning the Company and its officers’ possible violations of federal securities law. To obtain information or aid in the investigation, please visit the Novan investigation page on our website at www.glancylaw.com/case/novan-inc.
On January 27, 2017, the Company announced that its two “replicate” Phase 3 clinical trials for its topical acne treatment had yielded different results. The Company revealed that one trial showed statistical significance for all three co-primary endpoints and the other trial showed statistical significance for only one co-primary endpoint.
On this news, shares of Novan fell 74% to a close of $4.86 per share on January 27, 2017.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Novan securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
